Skip to main content
Erschienen in: BMC Medicine 1/2018

Open Access 01.12.2018 | Correction

Correction to: In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

verfasst von: I. Sermet-Gaudelus, M. Renouil, A. Fajac, L. Bidou, B. Parbaille, S. Pierrot, N. Davy, E. Bismuth, P. Reinert, G. Lenoir, J. F. Lesure, J. P. Rousset, A. Edelman

Erschienen in: BMC Medicine | Ausgabe 1/2018

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​1741-7015-5-5

Correction

The original article [1] contains errors in Table 1 affecting some of the presented oligonucleotide sequences and readthrough values in Table 1.
Table 1
Oligonucleotide sequences used in the dual reporter gene assay, corresponding to the Y122X, G542X, R1162X and W1292X mutations and the TQ in frame control. Readthrough level before and after incubation with 600 μg/ml gentamicin
Mutation
Oligonucleotide
0
600
Y122X
w 5’ TCTATCGCGATTTAACTAGGCATAGGC 3′
c 5’ GCCTATGCCTAGTTAAATCGCGATAGA 3′
0.02
0.12
W1282X
w 5’ACTTTGCAACAGTGAAGGAAAGCCTTT 3′
c 5’AAAGGCTTTCCTTCACTGTTGCAAAGT 3’
0.115
0. 35
R1162X
w 5’CGATCTGTGAGCTGAGTCTTTAAGTTC 3′
c 5’GAACTTAAAGACTCAGCTCACAGATCG 3′
0.023
0.22
G542X
w 5’AATATAGTTCTTTGAGAAGGTGGAATC 3′
c 5’GATTCCACCTTCTCAAAGAACTATATT 3′
0.017
0.26
The corrected Table 1 displayed below shows the correct presentation of the affected oligonucleotide sequences for mutations Y122X, W128X, and G542X, as well as the correct readthrough values in columns ‘0’ and ‘600’ for the Y122X mutation. These corrections also extend to the corresponding data mentioned in the first paragraph of the Results section and Supplemental Table 1. Whatever the mutation, gentamicin induced readthrough remained very moderate which explains the absence of changes in patients harboring G542X, R1162X and W1282X mutation. This is in contrast to Y122X patients, who unexpectedly demonstrated restoration of adequate levels of functional protein in vivo inspite of low readthrough levels observed in vitro. One explanation could be a lower efficiency of the nonsense mediated mRNA (NMD) pathway in the cells of these patients, which can not be revealed with the dual reporter system.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study
verfasst von
I. Sermet-Gaudelus
M. Renouil
A. Fajac
L. Bidou
B. Parbaille
S. Pierrot
N. Davy
E. Bismuth
P. Reinert
G. Lenoir
J. F. Lesure
J. P. Rousset
A. Edelman
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Medicine / Ausgabe 1/2018
Elektronische ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-018-1138-z

Weitere Artikel der Ausgabe 1/2018

BMC Medicine 1/2018 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.